Enrollment Closed

A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection Read More at Micobiome.Ferring.com Read More at Rebiotix News Informed Consent Disclosure

A phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, Immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals.

Read more at Pfizer News Read More at Medical Xpress Read More at Clinical Trails Arena Updated General Eligibility Criteria 2021 Final Informed Consent Disclosure